The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

Rheumatology (United Kingdom)

Volumn 52, Issue 10, 2013, Pages 1845-1855

  Furst, Daniel E ^a   Kay, Jonathan ^b   Wasko, Mary Chester ^c   Keystone, Edward ^d   Kavanaugh, Arthur ^e   Deodhar, Atul ^f   Murphy, Frederick T ^g   Magnus, Jeanette H ^h   Hsia, Elizabeth C ^i,j   Hsu, Benjamin ⁱ   Xu, Stephen ⁱ   Rahman, Mahboob U ^i,j   Doyle, Mittie K ^i,j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Altoona Center of Clinical Research   (United States)

^h TULANE UNIVERSITY   (United States)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Anaemia; Ankylosing spondylitis; Anti TNF agent; Golimumab; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

FERRITIN; GOLIMUMAB; HEMOGLOBIN; METHOTREXATE;

ADULT; ANEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 84887358930     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket233     Document Type: Article

References (26)

1. Wilson A, Yu HT, Goodnough LT et al. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):50S-57S.
2. Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol 2006;33:1516-22.
3. Han C, Rahman MU, Doyle MK et al. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 2007;34:2177-82.
4. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
5. Papadaki HA, Kritikos HD, Valatas V et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-a antibody therapy. Blood 2002;100:474-82.
6. Roy CN, Andrews NC. Anemia of inflammation: the hepcidin link. Curr Opin Hematol 2005;12:107-11.
7. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
8. Vreugdenhil G, Löwenberg B, van Eijk HG et al. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992;22:488-93.
9. Jongen-Lavrencic M, Peeters HR, Wognum A et al. Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J Rheumatol 1997;24:1504-9.
10. Davis D, Charles PJ, Potter A et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor a blockade. Br J Rheumatol 1997;36:950-6.
11. Doyle MK, Rahman MU, Han C et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum 2008;39:123-31.
12. Emery P, Fleischmann RM, Moreland LW et al. Golimumab, a human anti-tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
13. Keystone EC, Genovese MC, Klareskog L et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
14. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
15. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor a antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
16. Inman RD, Davis JC Jr, van der Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
17. Prevoo ML, van 't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
18. Prevoo ML, van Gestel AM, van't Hof MA et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
19. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
20. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
21. Shanahan JC, St Clair W. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. Clin Immunol 2002;103(3 Pt 1):231-42.
22. Rahman MU, Buchanan J, Doyle MK et al. Changes in patient characteristics in anti-tumor necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 2011;70:1631-40.
23. Vreugdenhil G, Wognum AW, van Eijk HG et al. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis 1990;49:93-8.
24. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007;6:457-63.
25. Demirag MD, Haznedaroglu S, Sancak B et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med 2009;48:421-6.
26. Braun J, Brandt J, Listing J et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a threemonth, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.